[PDF] Top 20 Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma
Has 10000 "Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma" found on our website. Below are the top 20 most common "Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma".
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma
... 23. Tichelaar JW, Lu W, and Whitsett JA. Conditional expression of fibroblast growth factor-7 in the developing and mature lung. J Biol Chem. 2000;275(16):11858-64. 24. Zheng Y, de la Cruz CC, Sayles LC, ... Voir le document complet
46
Implicating the mechanisms of ADP-ribosylation factor activation in the resistance of invasive breast cancer cells to EGFR tyrosine kinase inhibitors
... p38MAPK inhibitors in both cancer and inflammation. In inflammation, p38MAPK inhibitors have been shown to down-regulate an inflammatory response as measured by a decreased cytokine ... Voir le document complet
270
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
... Targeting EGFR with kinase inhibitors alone All the cells were treated with reversible EGFR TKIs gefitinib and erlotinib, and the covalent inhibitor afatinib (targeting both EGFR and ... Voir le document complet
15
Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.: Areg and gefitinib resistance in NSCLC
... involved in the development of various human cancers. In NSCLC, EGFR is frequently overexpressed and associated with a poor prognosis of patients ...[2]. In the last decade, a novel class of ... Voir le document complet
34
Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme
... wild-type EGFR and loss of the tumor suppressor genes Ink4a/Arf and PTEN are salient features of this deadly ...targeted inhibition of EGFR has been clinically disappointing, demonstrating an innate ... Voir le document complet
22
en fr Identification and vectorization of combination of drugs for the treatment of lung tumors resistant to EGFR tyrosine kinase inhibitors Identification et vectorisation de combinaisons de traitements pour la thérapie des tumeurs pulmonaires résistantes aux inhibiteurs de tyrosine kinase de l'EGFR
... apoptosis in NSCLC cells via activation of ...described in Figure ...gefitinib resistance by PI3K/AKT and HDAC in mutant KRAS lung adenocarcinoma ...cells. In the presence ... Voir le document complet
251
Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
... target in non-small cell lung can- cer ...confer resistance to current available agents, especially the fre- quently occurring T790M ...mutation. In the current study, we have examined, ... Voir le document complet
7
Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
... expressed in MDA-MB-468 cells, five genes involved in cell cycle progression (CCNA1, CCNB1, CCND1, CCNE1, CHEK1) were down-regulated by anti-EGFR ...and EGFR-TKIs significantly reduced ... Voir le document complet
21
The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism
... receptor tyrosine kinase inhibitors (EGFR-TKIs), it is important to gain a better understanding of the intracellular pathways leading to EGFR-TKI resistance, which ... Voir le document complet
14
The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism
... activity in NSCLC. RHOB expression is downregulated in aggressive tumors, and we have shown that the loss of RHOB is associated with decreased overall survival in two independent series of patients ... Voir le document complet
14
The RAS ‐related GTP ase RHOB confers resistance to EGFR ‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT ‐dependent mechanism
... activity in NSCLC. RHOB expression is downregulated in aggressive tumors, and we have shown that the loss of RHOB is associated with decreased overall survival in two independent series of patients ... Voir le document complet
14
en fr Alteration of radiation response by two tyrosine kinase inhibitors: STI571 (Glivec®) and BIBW 2992 Étude de l'altération de la réponse aux radiations ionisantes par deux inhibiteurs de tyrosine kinase : le STI571 (Glivec®) et le BIBW 2992
... L’effet radiosensibilisateur du ST571 sur les cellules de LMC a été confirmé sur d’autres types cellulaires que la lignée K562. Cependant, les débouchés thérapeutiques de l’association du STI571 à l’irradiation ... Voir le document complet
187
Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
... blockade, in mouse xenografts specifically affecting the epithelial component of the ...shown to surpass single therapy in inhibiting tumor activity in a NSCLC xenograft model with high ... Voir le document complet
13
Tyrosine kinase syk non-enzymatic inhibitors and potential anti-allergic drug-like compounds discovered by virtual and in vitro screening.
... experiment in which FcεRI-dependent degranulation of mast cells was performed in parallel with ionomycin-induced degranulation as a control of the degranulation ...belongs to cluster 2 and molecule ... Voir le document complet
25
Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
... used to treat melanoma, with very encouraging results, ICIs have been tested in many other tumor types with demonstrated clinical efficacy [ 2 ...primary resistance to ICIs, while others with ... Voir le document complet
31
Le récepteur tyrosine kinase c-Kit - Une nouvelle cible pour les antalgiques ?
... activité tyrosine kinase c-Kit et son ligand le SCF (stem cell factor) sont exprimés dans une grande variété de tissus où ils modulent une pléthore d’effets ...neurones in vitro [17] ... Voir le document complet
3
Marketing tools to improve Tyrosine Kinase Inhibitors compliance for patients with Chronic Myeloid Leukemia: an achievable strategy for pharmaceutical industries?
... According to Eric Baseilhac, former director of the LEEM (“Les Entreprises du Médicament”), drugs prices are negotiated with the CEPS (Comité Economique des Produits de Santé) according to ...subject ... Voir le document complet
90
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.
... Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu 夽,夽夽 J. De Grève a , ∗ , E. Teugels a , C. Geers a , L. ... Voir le document complet
5
Bimodal Fluorescence/{129}Xe NMR Probe for Molecular Imaging and Biological Inhibition of EGFR in Non-Small Cell Lung Cancer
... of EGFR and they display inhibited proliferation in response to the cetuximab treatment (See ...C1 in dose-related manner which correlated with EGFR expression ...with EGFR ... Voir le document complet
8
Association between texture analysis parameters and biomarkers (EGFR, KRAS, ALK) in pulmonary adenocarcinoma
... primary lung adenocarcinoma were included in this monocentric retrospective ...study. EGFR mutations, KRAS mutations and ALK rearrangements were systematically ...relative to pixel ... Voir le document complet
33
Sujets connexes